Most cited papers from Andover Eye Associates

Andover Eye Associates

What are the most cited papers from Andover Eye Associates?

The most cited paper from Andover Eye Associates is "Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction" (Jesse C. Chow, Donna W. Young, Douglas Taylor Golenbock et al., 1999), with 1,974 citations. Next come "Medicinal chemical properties of successful central nervous system drugs" (1,547) and "Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris" (900).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 72 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction Jesse C. Chow, Donna W. Young, Douglas Taylor Golenbock et al. · Journal of Biological Chemistry Open access	Apr 1999	1,974
2	Medicinal chemical properties of successful central nervous system drugs Hassan Pajouhesh, George R. Lenz · NeuroRx Open access	15 Sep 2005	1,547
3	Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris Edmund Lee, William L. Trepicchio, Judith L. Oestreicher et al. · The Journal of Experimental Medicine Open access	5 Jan 2004	900
4	Damage correlations in semiconductors exposed to gamma, electron and proton radiations Geoffrey P. Summers, E.A. Burke, Philip E. Shapiro et al. · IEEE Transactions on Nuclear Science	Dec 1993	561
5	A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer Dipen J. Parekh et al. · European Urology	27 Oct 2014	418
6	E5531, a Pure Endotoxin Antagonist of High Potency William J. Christ et al. · Science	7 Apr 1995	324
7	Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments Frank Loganzo et al. · Molecular Cancer Therapeutics	2 Feb 2015	279
8	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer Martin Jean Schlumberger, Barbara Jarząb, Maria E. Cabanillas et al. · Clinical Cancer Research Open access	26 Aug 2015	251
9	Gain, Phase Imbalance, and Phase Noise Effects on Error Vector Magnitude Apostolos Georgiadis · IEEE Transactions on Vehicular Technology	Mar 2004	248
10	Transient photoconductivity and photo-induced optical absorption in amorphous semiconductors J. Orenstein, M. A. Kastner, V. Vaninov · Philosophical Magazine B	Jul 1982	242
11	Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease John D. Sheppard, Gail L. Torkildsen, John D. Lonsdale et al. · Ophthalmology	27 Nov 2013	221
12	Viral contamination in biologic manufacture and implications for emerging therapies Paul W. Barone et al. · Nature Biotechnology Open access	27 Apr 2020	215
13	Ancient Mesoamerican Civilization Richard S. MacNeish · Science	7 Feb 1964	200
14	Deep phenotyping: The details of disease Cathryn M. Delude · Nature Open access	Nov 2015	199
15	The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult John M. Wozney · European Journal Of Oral Sciences	1998	180
16	Alternative Reference Values for Tear Film Break up Time in Normal and Dry Eye Populations Mark B. Abelson, George W Ousler, Lauren A. Nally et al. · Advances in experimental medicine and biology Book chapter	2002	166
17	Introduction to functional analysis James T. Chok, Jill M. Harper, Mary Jane Weiss et al. · Elsevier eBooks Book chapter	27 Sep 2019	159
18	Idiopathic Pulmonary Fibrosis in United States Automated Claims: Incidence, Prevalence, and Algorithm Validation Daina B. Esposito, Stephan Lanes, Macarius M. Donneyong et al. · American Journal of Respiratory and Critical Care Medicine	4 Aug 2015	157
19	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Jaya Julie Joshi et al. · Cancer Research	14 Dec 2017	155
20	The Ocular Protection Index George W Ousler, Katrina Wilcox Hagberg, M.R. Schindelar et al. · Cornea	22 May 2008	139
21	Computational tool for the early screening of monoclonal antibodies for their viscosities Neeraj J. Agrawal, Bernhard Helk, Sandeep Kumar et al. · mAbs Open access	23 Sep 2015	138
22	Immune dysregulation mediated by the oral microbiome: potential link to chronic inflammation and atherosclerosis Connie Slocum, Christine Krämer, Caroline Attardo Genco · Journal of Internal Medicine	21 Jan 2016	137
23	Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat J Z Li, H Li, Tsutomu Sasaki et al. · Gene Therapy	26 Aug 2003	135
24	Sleep patterns predictive of daytime challenging behavior in individuals with low‐functioning autism Simonne Cohen, Ben Fulcher, Shantha M. W. Rajaratnam et al. · Autism Research	Dec 2017	123
25	Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer Xiaoling Puyang et al. · Cancer Discovery	10 Jul 2018	119
26	Rational design of viscosity reducing mutants of a monoclonal antibody: Hydrophobic versus electrostatic inter-molecular interactions Pilarin Nichols, Li Li, Sandeep Kumar et al. · mAbs Open access	2 Jan 2015	118
27	Recombinant human factor VIII‐specific affinity ligands selected from phage‐displayed combinatorial libraries of protein A Karin Nord, Olof Nord, Mathias Uhlén et al. · European Journal of Biochemistry	Aug 2001	116
28	SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model Anton Petrov, Natalia Perekhvatova, Maxim V. Skulachev et al. · Advances in Therapy Open access	2016	112
29	Optical spectra and pigmentation of Caribbean reef corals and macroalgae Monique R. Myers, John T. Hardy, Charles H. Mazel et al. · Coral Reefs	24 Jul 1999	111
30	A Gas-Permeable Scleral Contact Lens for Visual Rehabilitation Oliver D. Schein, Perry Rosenthal, Christopher Ducharme · American Journal of Ophthalmology	Mar 1990	110
31	A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye Charles P. Semba, Gail L. Torkildsen, John D. Lonsdale et al. · American Journal of Ophthalmology	11 Feb 2012	109
32	Discovery of Anticancer Agents of Diverse Natural Origin Alan Douglas Kinghorn, Esperanza J. Carcache de Blanco, David M Lucas et al. · Anticancer Research Open access	28 Oct 2016	107
33	Clinically accurate fetal ECG parameters acquired from maternal abdominal sensors Gari D. Clifford, Reza Sameni, Jay Ward et al. · American Journal of Obstetrics and Gynecology Open access	7 Mar 2011	107
34	Skeletal Trauma in Child Abuse: Detection with18F-NaF PET Laura A. Drubach, Patrick R. Johnston, A Newton et al. · Radiology	22 Mar 2010	105
35	CD11/CD18 and CD14 Share a Common Lipid A Signaling Pathway Robin R. Ingalls, Brian G. Monks, R Savedra et al. · The Journal of Immunology Open access	Nov 1998	99
36	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper Oliver Pfaar et al. · Allergy Open access	25 Jan 2017	97
37	Anonymous refereeing Robert K. Adair, Hugh R. Carlon, Christopher Sherman · Physics Today	Jun 1981	96
38	Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis Ila Joshi, Walter P. Carney, Edwin P. Rock · Frontiers in Immunology Open access	7 Feb 2023	94
39	Autism spectrum disorder and the student teacher relationship: A comparison study with peers with intellectual disability and typical development Jan Blacher, Erica Howell, Stacy Lauderdale-Littin et al. · Research in Autism	20 Jan 2014	93
40	The radiobiological principles of boron neutron capture therapy: A critical review J. W. Hopewell, Garrett M. Morris, Amanda Elena Schwint et al. · Applied Radiation and Isotopes	24 Apr 2011	91
41	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program Edward Anders Kolb, Richard Greg Gorlick, C. Patrick Reynolds et al. · Pediatric Blood & Cancer Open access	28 Mar 2013	90
42	Muscarinic receptor-mediated tyrosine phosphorylation of phospholipase C-gamma. An alternative mechanism for cholinergic-induced phosphoinositide breakdown. Fabian Gusovsky, John Lueders, Elise C. Kohn et al. · Journal of Biological Chemistry Open access	Apr 1993	90
43	Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management Stacey L. Ackerman, Lisa Michelle Smith, P.J. Gomes · Therapeutic Advances in Chronic Disease Open access	2016	87
44	A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease David Wirta, Gail L. Torkildsen, Helen R. Moreira et al. · Ophthalmology Open access	28 Jan 2019	86
45	Measuring Outcomes of Vision Rehabilitation with the Veterans Affairs Low Vision Visual Functioning Questionnaire Joan A. Stelmack, Janet P. Szlyk, Thomas R. Stelmack et al. · Investigative Ophthalmology & Visual Science	28 Jul 2006	86
46	Diurnal Variation of Visual Function and the Signs and Symptoms of Dry Eye Pamela M. Walker, Keith Jeffrey Lane, George W Ousler et al. · Cornea	11 May 2010	86
47	Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity Mark B. Abelson, Lawrence Spitalny · American Journal of Ophthalmology	Jun 1998	86
48	Blink: Characteristics, Controls, and Relation to Dry Eyes John David Rodriguez, Keith Jeffrey Lane, George W Ousler et al. · Current Eye Research	18 Oct 2017	85
49	Ocular Allergic Disease: Mechanisms, Disease Sub-types, Treatment Mark B. Abelson, Lisa Michelle Smith, Matthew J. Chapin · The Ocular Surface	Jul 2003	82
50	Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial James T. McLaughlin, Patane, Cohen et al. · Clinical ophthalmology Open access	May 2011	82

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.